Eric Schadt, PhD, on Predicting Disease Risk for Patients with Cancer

Article

The founder and CEO of Sema4 spoke about what health care providers currently lack in preventing and treating diseases and what the reality of early detection and disease prevention can provide to patients with cancer.

The current health care system uses basic tests to collect a fraction of the information available for predicting disease risk and changes in an individual’s health.

However, according to the developers of Sema4, a patient-centered health intelligence company, the data generated during routine testing and episodic physician visits is limited and inadequate for determining a patient’s risk in advance of the acute onset of disease.

In an interview with CancerNetwork®, Eric Schadt, PhD, founder and CEO of Sema4, as well as the dean for Precision Medicine and professor of Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai, Schadt discussed what health care providers currently lack in preventing and treating diseases and what the reality of early detection and disease prevention can provide to patients with cancer.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Sema4. Our Story. Sema4 website. Published 2020. Accessed December 3, 2020. https://sema4.com/our-story/

Recent Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content
Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.

Don Dizon, MD, on Improving Treatment Strategies for Transgender Patients With Cancer

Don S. Dizon, MD
November 28th 2021
Article

Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

Don Dizon, MD on the Experiences of Gay and Transgender Patients With Cancer

Don S. Dizon, MD
November 22nd 2021
Article

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

Don Dizon, MD on Challenges in Collecting Gender Identity and Sexual Orientation Data in Clinical Cancer Research

Don S. Dizon, MD
November 20th 2021
Article

Currently, it is not known whether cisgender and transgender patients with cancer respond similarly to standard-of-care therapies due to challenges collecting gender identity and sexual orientation data in clinical cancer research.

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Don Dizon, MD on Overcoming Barriers to LGBTQ+ Inclusivity in Clinical Cancer Research

Don S. Dizon, MD
November 19th 2021
Article

Don Dizon, MD, emphasizes the importance of policies ensuring higher levels of gay and transgender participation in clinical cancer trials.

Judd Moul, MD, Reviews Studies From 2021 ASCO Showing Systemic Therapy Advancements in Prostate Cancer

Judd Moul, MD, Reviews Studies From 2021 ASCO Showing Systemic Therapy Advancements in Prostate Cancer

Ariana Pelosci;Judd W. Moul, MD
July 29th 2021
Article

Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and how they can be of use during the COVID-19 pandemic.

Robert A. Figlin, MD, on the Potential Importance of Adjuvant IO in Bladder Cancer

Robert A. Figlin, MD, on the Potential Importance of Adjuvant IO in Bladder Cancer

Robert A. Figlin, MD
July 26th 2021
Article

Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.